NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

Rhea-AI Summary

NeuroSense (NASDAQ:NRSN) updated regulatory and clinical progress for lead asset PrimeC. A Health Canada pre‑NDS meeting was rescheduled to May 2026 to include additional clinical, biomarker and survival data intended to strengthen the submission.

The company expects an Alzheimer's study clinical and biomarker readout in the coming weeks and cites a previously disclosed 65% reduction in risk of death and FDA clearance to start the pivotal Phase 3 PARAGON ALS trial.

Positive

• Statistically significant survival benefit: 65% risk reduction
• Health Canada pre‑NDS targeted for May 2026 with expanded data
• FDA clearance received to initiate pivotal Phase 3 PARAGON in ALS
• Near‑term Alzheimer’s clinical and biomarker readout expected in coming weeks

Negative

• Pre‑NDS meeting rescheduled, delaying submission timeline to May 2026
• Regulatory strategy depends on inclusion of emerging data not yet publicly released

News Market Reaction – NRSN

-1.48% 2.3x vol

6 alerts

-1.48% News Effect

-22.2% Trough in 2 hr 31 min

-$391K Valuation Impact

$26.05M Market Cap

2.3x Rel. Volume

On the day this news was published, NRSN declined 1.48%, reflecting a mild negative market reaction. Argus tracked a trough of -22.2% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $391K from the company's valuation, bringing the market cap to $26.05M at that time. Trading volume was elevated at 2.3x the daily average, suggesting increased selling activity.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Risk of death reduction: 65% reduction Pre-NDS timing: May 2026

2 metrics

Risk of death reduction 65% reduction PrimeC survival benefit referenced as prior data supporting regulatory strategy

Pre-NDS timing May 2026 Rescheduled Health Canada pre-New Drug Submission meeting for PrimeC

Market Reality Check

Price: $0.7310 Vol: Volume 130,641 is at 0.78...

normal vol

$0.7310 Last Close

Volume Volume 130,641 is at 0.78x the 20-day average of 166,847, suggesting subdued trading ahead of this update. normal

Technical Shares at $0.741 are trading below the $1.24 200-day moving average, reflecting a longer-term downtrend.

Peers on Argus

Among key biotech peers, moves are mixed: one notable peer is down while several...

1 Up

Among key biotech peers, moves are mixed: one notable peer is down while several others are up (ITRM +7.18%, ALLR +3.64%, KZR +0.31%), diverging from NRSN’s -1.59% move and pointing to stock‑specific factors.

Historical Context

5 past events · Latest: Mar 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 18	Conference data update	Positive	-5.4%	Announcement of new clinical and biomarker data presentation for PrimeC at AD/PD 2026.
Mar 18	Correction notice	Positive	-5.4%	Clarified details on PrimeC ALS data presentation and Phase 3 PARAGON planning.
Mar 16	Peer-reviewed publication	Positive	+1.4%	JAMA Neurology publication of Phase 2b PARADIGM results showing functional and biomarker benefits.
Mar 09	Survival data preview	Positive	-3.0%	Long-term survival data presentation with 65% reduced death risk and >14‑month benefit.
Feb 18	Survival data release	Positive	-14.7%	Released extended PARADIGM survival data showing 36.3‑month median survival with PrimeC.

Pattern Detected

Recent positive ALS and regulatory milestones have often seen weak or negative next‑day price reactions, indicating a pattern of selling into good news.

Recent Company History

Over the past months, NeuroSense has highlighted increasingly positive data for PrimeC in ALS. On Feb 18, 2026, it reported a 65% mortality risk reduction and >14‑month survival gain, yet the stock moved -14.69%. Subsequent updates on long‑term survival, JAMA Neurology publication, and AD/PD 2026 presentations showed mixed to negative reactions. Today’s Health Canada pre‑NDS timing update and imminent Alzheimer’s readout continue this trajectory of advancing PrimeC while the share price lags fundamentals.

Regulatory & Risk Context

Active S-3 Shelf · $150,000,000

Shelf Active

Active S-3 Shelf Registration 2026-01-29

$150,000,000 registered capacity

An effective Form F-3 shelf dated 2026-01-29 allows NeuroSense to offer up to $150,000,000 in securities, including an at-the-market program of up to $6,525,000. The filing notes substantial doubt about going concern status and highlights the importance of future financings; no usage has been reported yet under this shelf.

Market Pulse Summary

This announcement reinforces NeuroSense’s strategy of leveraging an expanded dataset, including a 65...

Analysis

This announcement reinforces NeuroSense’s strategy of leveraging an expanded dataset, including a 65% mortality risk reduction and broader biomarker evidence, ahead of a rescheduled Health Canada pre-NDS meeting in May 2026. Imminent Alzheimer’s readouts add another catalyst alongside FDA-cleared Phase 3 ALS plans. Investors may monitor upcoming clinical data quality, regulatory feedback, and use of the $150,000,000 shelf and ATM program as key signals for execution and balance sheet risk.

Key Terms

pre-new drug submission, pre-nds, noc/c pathway, biomarker, +2 more

6 terms

pre-new drug submission regulatory

"A pre-New Drug Submission (pre-NDS) meeting with Health Canada has been rescheduled"

A pre-new drug submission is a planned discussion between a drug developer and a health regulator that happens before the company files its formal application to market a new medicine. Think of it as a dress rehearsal or checklist review where the regulator flags study gaps, data expectations, and regulatory requirements so the final application is less likely to be rejected or delayed; investors watch these meetings because they reduce uncertainty about approval timelines and costs.

pre-nds regulatory

"A pre-New Drug Submission (pre-NDS) meeting with Health Canada has been rescheduled"

pre-NDS (pre-New Drug Submission) describes the preparatory steps a drug developer takes before formally filing for regulatory approval of a new medicine, including data reviews, regulatory meetings and finalizing study results. For investors, pre-NDS activity is like a company rehearsing and checking equipment before a big product launch: it signals how close the drug is to an official approval request and helps gauge development risk and potential timing for future value milestones.

noc/c pathway regulatory

"advancing PrimeC under the NOC/c pathway in Canada, which is designed to facilitate"

A NOC/c pathway is a regulatory approval route in which a health authority grants conditional market authorization for a drug or medical product based on promising, but incomplete, evidence; the sponsor must complete additional studies or meet specific requirements after approval. For investors, it signals faster patient access and potential early revenue like a provisional license, but comes with higher uncertainty and the risk that follow-up data could change the product’s commercial prospects.

biomarker medical

"additional emerging clinical, biomarker and survival data and analyses in the briefing"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

phase 3 medical

"FDA clearance to initiate the pivotal Phase 3 PARAGON trial in ALS"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

pivotal medical

"FDA clearance to initiate the pivotal Phase 3 PARAGON trial in ALS"

Pivotal describes a test, event, or decision that is decisive for whether a product, idea, or plan moves forward—most often used for a late-stage clinical trial or a regulatory review whose result determines approval or rejection. Investors care because a positive outcome typically unlocks major value (like market access or sales), while a negative one can sharply reduce expected future revenue; think of it as the final exam that decides whether a project passes or fails.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today provided an update on key regulatory and clinical milestones for its lead asset, PrimeC.

 

 

Health Canada Pre-NDS Meeting

A pre-New Drug Submission (pre-NDS) meeting with Health Canada has been rescheduled to May 2026.

The decision was made to allow for the inclusion of additional emerging clinical, biomarker and survival data and analyses in the briefing package, which the Company believes will meaningfully strengthen the scientific and clinical foundation supporting PrimeC.

The Company remains focused on advancing PrimeC under the NOC/c pathway in Canada, which is designed to facilitate earlier access to promising therapies addressing serious unmet medical needs.

Alzheimer's Disease Program Update

The Company expects to report clinical and biomarker results from its Alzheimer's study in the coming weeks.

Continued Momentum Across Key Programs

NeuroSense continues to advance its clinical and regulatory strategy for PrimeC, supported by our previously disclosed:

• Statistically significant survival benefit (65% reduction in risk of death)
• Expanding biomarker dataset supporting multi-mechanistic activity
• FDA clearance to initiate the pivotal Phase 3 PARAGON trial in ALS

"As we generated additional valuable data, we believe it is strategic to incorporate these findings and analyses into our regulatory interactions," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "Our objective is to present the most comprehensive and robust dataset possible to Health Canada, thereby maximizing the likelihood of a constructive and efficient regulatory pathway. We believe this approach positions the Company ahead of several important value inflection points across its ALS and Alzheimer's programs expected in 2026."

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.

About ALS

Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, reporting of data, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding future development of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the timing of regulatory filings, meetings and regulatory decisions; outcomes and the timing of current and future clinical trials; the risk the PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/neurosense-advances-toward-key-regulatory-milestones-with-strengthened-data-package-and-near-term-alzheimers-readout-302723386.html

SOURCE NeuroSense

FAQ

Why was NeuroSense (NRSN) pre‑NDS meeting with Health Canada rescheduled to May 2026?

The meeting was rescheduled to allow inclusion of additional emerging clinical, biomarker and survival data. According to the company, adding these analyses is intended to strengthen the scientific and clinical briefing package for PrimeC.

When will NeuroSense (NRSN) report Alzheimer's study results for PrimeC?

NeuroSense expects to report clinical and biomarker results from its Alzheimer's study in the coming weeks. According to the company, these near‑term readouts are positioned as potential value inflection points in 2026 for the Alzheimer's program.

What survival benefit has NeuroSense reported for PrimeC and how material is it?

The company cites a statistically significant 65% reduction in risk of death for PrimeC. According to the company, this survival signal supports broader regulatory discussions and underpins continued advancement across key programs.

How does the May 2026 pre‑NDS timing affect NeuroSense's regulatory pathway for PrimeC in Canada?

Moving the pre‑NDS to May 2026 delays the immediate submission timeline but aims to strengthen the application. According to the company, the strategy is to improve the briefing package to support the NOC/c accelerated pathway.

What regulatory progress has NeuroSense (NRSN) achieved for PrimeC beyond Health Canada interactions?

NeuroSense obtained FDA clearance to initiate the pivotal Phase 3 PARAGON trial in ALS. According to the company, this FDA clearance and expanding biomarker dataset advance its clinical and regulatory strategy for PrimeC.